Advertisement


Daniel A. Goldstein, MD, on Pembrolizumab for Lung Cancer: Saving Costs by Adjusting Dosage

2017 ASCO Annual Meeting

Advertisement

Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-based doses instead of a predetermined fixed dose for treatment of PD-L1-positive non–small cell lung cancer. (Abstract 9013)



Related Videos

Prostate Cancer

Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide

Gerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)

Breast Cancer

Lisa A. Carey, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial

Lisa A. Carey, MD, of the University of North Carolina, and Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, discuss phase III study findings on olaparib monotherapy vs chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. (Abstract LBA4)

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)

Bladder Cancer

David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045

David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizumab vs paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer. (Abstract 4501)

Gastroesophageal Cancer

Salah-Eddin Al-Batran, MD, on GEJ Adenocarcinoma: Results From the FLOT4-AIO Trial

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research Krankenhaus Nordwest, discusses phase III study findings on perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin vs epirubicin, cisplatin, and fluorouracil or capecitabine for resectable gastric or gastroesophageal junction adenocarcinoma. (Abstract 4004)

Advertisement

Advertisement




Advertisement